A new drug for HIV treatment could hit the market within a year
Mylan has a big drug that could be on the market in less than a year.
The company announced a new drug on Wednesday that could help treat people with HIV who are too ill to take their own medicine.
The new drug, called nivolumab, is a combination of a two-drug combination, or “triple,” of the two drugs that were originally designed to fight HIV and other infectious diseases.
It was approved by the Food and Drug Administration in March.
“It’s the combination of the three drugs that was originally designed for HIV,” Mylan Chief Executive Officer Anthony Fauci said.
“It’s just a great combination.”
Mylan says it expects the drug will be available in a handful of U.S. markets in the first quarter of 2018.
The drug will target people who have not had the virus for a long time, Faucesaid.
It will also be able to help people who are already sick with an HIV-related condition and who have already tried multiple medications, he said.
Mylan’s other drugs include an anti-rejection drug called ritonavir and an antiretroviral drug called Daraprim.
I can’t emphasize enough how great this combination of drugs is.
-Anthony Fauccosaid, Mylan chief executiveThe drug, which is marketed under the brand name Viogenics, is currently under development and is in clinical trials, according to Mylan.
Its first phase I trials began in May.
Mylan is trying to get a patent granted by the U.K. in early 2018.
I have the utmost confidence that this combination, with its combination of powerful anti-retroviral and anti-cancer drugs, will be able and effective,” Faucia said.
It is the first drug in Mylan’s portfolio that can be sold in the United States.
The company said it expects to have the drug available in most U.M. states by the end of the first half of 2018, when it will start selling it through pharmacies.
Mylans drugs are also sold in other countries, including the United Kingdom, Canada and Australia.